# Research timeline and gaps: Lifestyle Weight Loss and MASH Reversal

Selected publication milestones, not an exhaustive history or discovery priority claim.

**2010 — Randomized assigned lifestyle improves NAS and steatosis; current component definitions and achieved-loss strata remain distinct.** [Original PMID19827166](https://pubmed.ncbi.nlm.nih.gov/19827166/).

**2011 — A shared lifestyle-trial molecular follow-up adds ceramide leads rather than an independent clinical outcome unit.** [Original PMID21794038](https://pubmed.ncbi.nlm.nih.gov/21794038/).

**2013 — Mediterranean-diet fat improvement without different loss separates diet composition from weight mediation.** [Original PMID23485520](https://pubmed.ncbi.nlm.nih.gov/23485520/).

**2015 — Large paired-biopsy lifestyle cohort makes achieved-loss resolution and regression associations visible.** [Original PMID25865049](https://pubmed.ncbi.nlm.nih.gov/25865049/).

**2016 — LEAN supplies a distinct randomized drug histology positive with incomplete endpoint biopsies.** [Original PMID26608256](https://pubmed.ncbi.nlm.nih.gov/26608256/).

**2016 — Pioglitazone improves pathology despite weight gain, challenging universal weight-loss necessity.** [Original PMID27322798](https://pubmed.ncbi.nlm.nih.gov/27322798/).

**2017 — Weight-maintained exercise reduces hepatic fat without proving inflammation or fibrosis reversal.** [Original PMID27521509](https://pubmed.ncbi.nlm.nih.gov/27521509/).

**2018 — FLINT achieved-weight posthoc analysis illustrates additive response and nonrandom mediation limits.** [Original PMID29333665](https://pubmed.ncbi.nlm.nih.gov/29333665/).

**2019 — Obeticholic acid separates a fibrosis positive from a nonsignificant steatohepatitis-resolution outcome.** [Original PMID31813633](https://pubmed.ncbi.nlm.nih.gov/31813633/).

**2020 — Five-year bariatric biopsies reveal durable observed resolution/regression with selective follow-up.** [Original PMID32553765](https://pubmed.ncbi.nlm.nih.gov/32553765/).

**2021 — Daily semaglutide shows resolution efficacy while categorical fibrosis is nonsignificant.** [Original PMID33185364](https://pubmed.ncbi.nlm.nih.gov/33185364/).

**2021 — Lanifibranor demonstrates clinical-pathology efficacy despite weight gain and dose-specific significance.** [Original PMID34670042](https://pubmed.ncbi.nlm.nih.gov/34670042/).

**2021 — SPLENDOR contributes observational long-term surgery-event evidence rather than a surrogate-based lifestyle proof.** [Original PMID34762106](https://pubmed.ncbi.nlm.nih.gov/34762106/).

**2023 — Randomized diet metabolic/weight improvements do not guarantee a biopsy difference.** [Original PMID36508737](https://pubmed.ncbi.nlm.nih.gov/36508737/).

**2023 — Compensated cirrhosis semaglutide has weight/MRI-fat benefit without a positive histologic endpoint.** [Original PMID36934740](https://pubmed.ncbi.nlm.nih.gov/36934740/).

**2023 — BRAVES provides an actual surgery-versus-lifestyle/best-care randomized biopsy comparison.** [Original PMID37088093](https://pubmed.ncbi.nlm.nih.gov/37088093/).

**2024 — MAESTRO-NASH establishes resmetirom histology efficacy for a separate liver-directed exposure.** [Original PMID38324483](https://pubmed.ncbi.nlm.nih.gov/38324483/).

**2024 — SYNERGY-NASH adds tirzepatide pathology positives, with missing biopsies and an attached erratum.** [Original PMID38856224](https://pubmed.ncbi.nlm.nih.gov/38856224/).

**2024 — A newer small lifestyle RCT reports explicit component/resolution benefits with average fibrosis unchanged and an unresolved count discrepancy.** [Original PMID38914313](https://pubmed.ncbi.nlm.nih.gov/38914313/).

**2025 — ESSENCE interim 72-week semaglutide pathology positives precede its ongoing longer clinical phase.** [Original PMID40305708](https://pubmed.ncbi.nlm.nih.gov/40305708/).

**2025 — SYNERGY responder/mediation analysis generates weight-related leads without randomized mediator identity.** [Original PMID41066427](https://pubmed.ncbi.nlm.nih.gov/41066427/).

**2026 — Older-adult GLP1 cohort associates exposure with hepatic outcomes while MACE is null; observational event evidence remains separate.** [Original PMID42765724](https://pubmed.ncbi.nlm.nih.gov/42765724/).

## Research gaps

Independent adequately powered current-resolution replication of assigned lifestyle in baseline MASH.

Source clarification of the nine-resolution/eight-ballooning-zero inconsistency in PMID38914313.

Isolated weight versus activity, diet composition and peripheral metabolic mediation.

Prospective stage/diabetes interaction mapping and paired-biopsy missingness sensitivity.

Controlled lifestyle fibrosis improvement and durability beyond active histology response.

Hard hepatic events and harms beyond short selected cohorts; full supplements and all complete papers remain unaudited.

## Boundary experiment

A multicentre lifestyle-versus-matched-support randomized trial enrolls baseline-biopsy MASH adults, stratifies fibrosis stage and diabetes before outcomes, and measures independently read paired inflammation/ballooning resolution at 52–104 weeks. Factorial diet/exercise and prospectively controlled energy/weight trajectories distinguish package efficacy from isolated mediator claims; retain all assigned participants and specify missing-biopsy sensitivity analyses. Extend blinded hepatic event follow-up.